Investors
- 12: BioPorto’s NGAL cutoff patent is issued in India
- 11: interim report Q1 2011
- 10: BioPorto’s NGAL cutoff patent is issued in Japan
- 09: Share capital and votes
- 08: Insider’s dealings
- 07: Issue of warrants in BioPorto A/S
- 06: Increase of share capital following exercise of warrants and conversion of bonds
- 05: Development of Annual General Meeting
- 04: Annual General Meeting
- 03: Annual Report 2010
- 02: BioPorto sells NGAL license to major diagnostic company
- 01: BioPorto launches The NGAL Test™ for diagnostic use
- 15: Financial Calendar for 2011
- 14: Prospekt
- 13: Q3 interim report
- 12: Dako brings BioPorto’s kidney injury test to the world market
- 11: BioPorto pre-launches pioneering kidney injury test
- 10: BioPorto completes the subscription of convertible bonds
- 09: Subscription and issue of convertible bonds
- 08: Interim Financial Report for Q2 2010
- 07: BioPorto’s NGAL test approved for use by leading U.S. reference laboratory
- 06: BioPorto’s patent rights for NGAL - opposition to the European patent
- Newsletter July 2010
- 05: Interim financial report Q1
- 04: Development of Annual General Meeting
- 03: Insider's dealings
- 02: Annual General Meeting
- 01: Annual Report 2009
- Newsletter January 2010
- 29: Financial calendar 2010
- 28: Interim financial report for Q3 2009
- 27: Share Capital and Votes
- 26: EPO decides to issue BioPorto’s NGAL cutoff patent on November 11, 2009
- 25: Company articles
- 24: BioPorto completes cash issue
- 23: CCH drops lawsuit
- 22: Cash issue, private placement
- 21: Interim Financial Report for Q2 2009
- Documentation: EPO's reply to 3rd party
- 20: BioPorto adopts new rapid route to widespread commercialization of kidney test
- 19: EPO maintains October 1, 2009, as the date of resumption of patent grant proceedings
- 18: Objections from CCH against the resumption of grant proceedings
- 17: Insider's dealings
- 16: Insider's dealings
- 15: Insider's dealings
- 14: Interim financial report for Q1
- 13: Change of date for resumption
- 12: Resumption of proceedings for BioPorto's patent
- 11: Issue of warrants in BioPorto A/S
- 10: Insider's dealings
- 09: Development of annual general meeting
- 08: Insider's dealings
- 07: Insider's dealings
- 06: Insider's dealings
- 05: Insider's dealings
- 04: Annual General Meeting
- 03: Launch of APC-PCI ELISA Kit
- 02: Annual Report 2008
- 01: BioPorto's cutoff patent for NGAL – grant proceedings stayed
Newsletter July 2010
July 02 2010
BioPorto kunne i Q1 meddele, at selskabets nye homogne NGAL test er færdigudviklet og at testen nu er i opskaleringsfasen samt at forberedelserne til lancering af testen primo 2011 for alvor er startet. Dette nyhedsbrev har til formål at forklare nærmere om de forskellige stadier, som testen skal gennemgå frem til lancering er mulig. Der gives samtidig et kort oprids af mulighederne for distribution og salg af den nye test samt en overordnet tidslinje.
Download nyhedsbrevet i højre side.
